Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

NanoBio (Ann Arbor, MI), a clinical-stage biotechnology company focused on anti-infective intranasal & intramuscular vaccines for influenza, closed an $11M Series C financing. Participants include Perseus and Venture Investors.

Genocea Biosciences (Cambridge, MA), a clinical-stage biotechnology company focused on therapeutic and prophylactic vaccines for infectious diseases, closed a $30M Series C financing. Participants include Bill & Melinda Gates Foundation, Central Valley Fund, Johnson & Johnson Development Corp., Skyline Ventures, MP Healthcare Venture Management, Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga […]

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

Hookipa Biotech (Austria) a development-stage pharmaceutical company focused on prophylactic and therapeutic vaccines for viral diseases, closed $9.7M Series A financing. Participants include Sofinnova Partners and Forbion Capital Partners.

Selecta Biosciences (Watertown, MA) a clinical-stage biopharmaceutical company focused on a new class of vaccines and immunotherapies for nicotine addiction, cancer, diabetes, influenza and human papilloma virus (HPV) closed a $47.25M Series D financing. Participants include Rusnano.

ImmusanT (Cambridge, MA) a clinical-stage biopharmaceutical company focused on a peptide-based vaccine for celiac disease, closed a $20M Series A financing. Participants include Vatera Healthcare Partners.

Aduro Biotech (Berkeley, CA) a clinical-stage therapeutic immunotherapy vaccine company focused on cancer and infectious disease, closed a $19.2M Series B financing. Participants include Morningside Ventures.

Vaximm (Switzerland) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for various solid tumors, closed a $8M Series B financing. Participants include BB Biotech Ventures, Sunstone Capital, Merck Serono Ventures and BioMedPartners.

Kite Pharma (Los Angeles, CA) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for renal cell carcinoma and hepatocellular carcinoma, closed a $15M Series A financing. Participants include TPG Capital.

Genocea Biosciences (Cambridge, MA) a preclinical-stage therapeutic vaccine developer focused on chlamydia trachomatis, streptococcus pneumonia and herpes simplex virus type 2 infections, closed a $35M Series B financing. Participants include Johnson & Johnson Dev Corp., Skyline Ventures, MP Healthcare Management, SR One, Auriga Partners, Cycad Group, Alexandria Real Estate Equities, Lux Capital Management, Polaris Venture […]

Immune Design (Seattle, WA) a development-stage therapeutic vaccine company focused on oncology and infectious disease, closed a $32M Series B financing. Participants include ProQuest Investments, Column Group, Versant Ventures and Alta Partners.

Immatics Biotechnologies (Germany) a clinical-stage biotechnology company focused on therapeutic vaccines against renal and colorectal cancers, closed a $71M Series C financing. Participants include dievini Hopp Biotech, Wellington Partners and MIG Verwaltungs.

Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.

« Previous Entries  Next Page »

to top of page...